论文部分内容阅读
应用免疫组化技术检测了30例乳腺导管上皮增生(增生组,其中一般增生18例,不典型增生12例)、40例导管癌(癌组)和20例正常副乳腺(正常组)患者的p~(53)和c-erbB-2癌基因产物的表达及其分布。结果;增生组、癌组和正常的p~(53)蛋白阳性表达率分别为0、17.5%和0,c-erbB-2蛋白阳性表达率分别为26.7%,37.5%和0,三组间差异显著(均P<0.005)。并且增生组中不典型增生的c-erbB-2蛋白阳性率(50%)显著高于一般增生(11.1%,P<0.05)。提示c-erbB-2和p~(53)的检测在评估乳腺导管上皮不典型增生及其恶变潜能方面可能具有一定的参考价值。
Immunohistochemical technique was used to detect 30 cases of breast ductal hyperplasia (proliferative group, 18 cases of general hyperplasia, 12 cases of atypical hyperplasia), 40 cases of ductal carcinoma (cancer group) and 20 cases of normal deputy breast (normal group) patients. The expression and distribution of p53 and c-erbB-2 oncogene products. Results; The positive expression rates of p53 protein in hyperplasia group, cancer group and normal group were 0, 17.5% and 0 respectively, and the positive expression rates of c-erbB-2 protein were 26.7%, 37.5% and 0, respectively. The difference was significant (all P<0.005). The positive rate of c-erbB-2 protein in atypical hyperplasia in hyperplasia group (50%) was significantly higher than that in general hyperplasia (11.1%, P<0.05). It is suggested that the detection of c-erbB-2 and p53 may have a certain reference value in evaluating the atypical hyperplasia and malignant potential of breast ductal epithelium.